🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Mucinous lung adenocarcinoma (LUAD-Muc) is a WHO-recognized rare subtype of LUAD. Our study in Annals of Oncology aimed to characterize clinicopathologic, genomic, immunophenotypic & transcriptional features differentiating these tumors form other LUADs 1/9 annalsofoncology.org/article/S0923-…

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in #NSCLC Harboring BRAF Class 3 Mutations: brnw.ch/21wPx5U Authored by Alessandro Di Federico, Arianna Palladini Andrea De Giglio, MD PhD et al. #lcsm #LungCancer

⚠️Great to keep contributing to this ongoing effort by #MehrdadRakaee and collaborators! Dana-Farber Histology slides are widely available and can harbor useful information in low-resource settings. This is 1 application in the NSCLC/ICI space. #lcsm jamanetwork.com/journals/jamao…

Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer Out on JAMA Oncology This study highlights the importance of identifying patients with advanced non-small cell lung cancer (NSCLC) who are most likely to benefit from immune checkpoint

🚨Glad to see this collaborative effort finally out in JAMA Oncology! We developed a deep learning model (#DeepIO) to predict #ICI responses in #NSCLC directly from a single H&E-stained slide. #DeepIO showed improved accuracy vs known biomarkers (eg TILs, TMB, PD-L1). OncoAlert

Datopotamab Deruxtecan in Advanced or Metastatic #NCLC With Actionable Genomic Alterations: Phase II TROPION-Lung05 Study. Journal of Clinical Oncology 📊ORR in all pts: 35.8% 🧬In #EGFR+ #NSCLC: ORR 43.6%, PFS 5.8 mo, OS 18.3 mo Grade ≥3 TRAEs: 28.5% of patients w/ 5 patients experienced

Will the future of lung cancer biomarkers be based on deep learning and #AI? Deep learning model predicts response to immunotherapy in NSCLC from one histology slide and performed better than TMB, PD-L1. Report JAMA Oncology. jamanetwork.com/journals/jamao…

How do copy no. deletions in STK11, KEAP1 &SMARCA4 impact outcomes in NSCLC? -3194 nonsqNSCLCs: 14.7% STK11del 13.5% KEAP1del 13.7% SMARCA4del -assoc w ⬇️PD-L1, TMB -assoc w ⬇️ORR, PFS, OS from chemoIO in DFCI & MSKCC cohorts OncoAlert JTO & JTO CRR #LCSM jto.org/article/S1556-…

Chromothripsis-Mediated Small Cell Lung Carcinoma Cancer Discovery aacrjournals.org/cancerdiscover…

New #JITC article: Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry bit.ly/3QxbQBD Jarushka Naidoo João Alessi, MD Alessandro Russo

Proud of Federica Pecci for her amazing talk at #TTLC25 on our collaborative study comparing #MET TKIs vs #ICI for pts w/ METex14 #NSCLC. Co-led w/ ✨Xiuning Le MD PhD ✨this work provides key insights for personalized tx strategies for MET+ NSCLC. MD Anderson Cancer Center & Dana-Farber News.

Many different alterations in #MET can be targeted. Exon 14 skip mutations, fusions, amplifications - reminder in JTO & JTO CRR that MET TKD mutations are also relevant. Incidence ~0.15% and while they can be de novo, about 1/2 co-exist with other drivers. jto.org/article/S1556-…

Finally published in Cancer Discovery our work reporting a preliminary analysis from a phase 2 clinical trial of the type I MET tyrosine kinase inhibitor vebreltinib in MET fusion-positive solid tumors and a comprehensive characterization of MET rearrangements doi.org/10.1158/2159-8…

In a new study published in Clinical Cancer Research, Dana-Farber researchers found the effects of immunotherapy can last after treatment stops in patients with advanced non-small cell lung cancer. Dana-Farber's Lowe Center for Thoracic Oncology Read more: bit.ly/3GhpAhM

Just published in Clinical Cancer Research our work studying factors associated with prolonged disease control and survival after discontinuation of immune checkpoint inhibitors for irAEs in patients with advanced NSCLC. Mark Awad Rohit Thummalapalli Adam J. Schoenfeld doi.org/10.1158/1078-0…

Zoldonrasib (mutant selective covalent inhibitor targeting the ‘ON’ state of RAS G12D. Most patients were PDAC but included NSCLC. #AACR25 KRASKickers AACR #lcsm

Still struck by the impact our microbiome has on efficacy (and toxicity) of immunotherapy in lung cancer. Listen to this episode of the IASLC podcast, Lung Cancer Considered, where I discuss the data with Drs. Arielle Elkrief and Bertrand Routy. iaslc.org/iaslc-news/lun…

‼️Excited to share our ASCO edu book article on DLL3 targeting in SCLC. Probably one of the most extensive and Upto date reviews on this topic! Led by Ayesha Aijaz Sagal Pannu We talk about biology, trials, other T cell engagers , tox and much more! ascopubs.org/doi/10.1200/ED…

🎥 Alessandro Di Federico of Dana-Farber highlights key biomarkers from FRONT-BRAF: PD-L1 ≥1%, smoking history & TP53 co-mutations predict better outcomes with immunotherapy in BRAF-mutated lung cancer. 📺 Watch ➡ ow.ly/9oZ250W4OOj ASCO #ASCO25 #LungCancer #NSCLC #ImmunoOnc

Such a privilege to listen to Dr. Crinò—my first mentor—reflecting on 20 years of progress in #LungCancer treatment, from targeted therapies to immunotherapies. A masterclass in science and dedication in #Ferrara 🇮🇹. OncoAlert Dana-Farber Isabella Soares